Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer

Trends in Immunology

Volumn 24, Issue 7, 2003, Pages 395-402

  Signore, Alberto ^a   Capriotti, Gabriela ^a   Scopinaro, Francesco ^a   Bonanno, Elena ^b   Modesti, Andrea ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GROWTH FACTOR; INDIUM 111; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; IODINE 123; IODINE 125; IODINE 131; LYMPHOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; STROMAL CELL DERIVED FACTOR 1ALPHA; TECHNETIUM 99M; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ACUTE DISEASE; BINDING AFFINITY; CANCER CELL; CANCER LOCALIZATION; CELL ACTIVITY; CELL POPULATION; CHRONIC DISEASE; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION; INFLAMMATION; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PATIENT SELECTION; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SCINTIGRAPHY; T LYMPHOCYTE; TARGET CELL; TREATMENT INDICATION;

EID: 0038644077     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(03)00174-1     Document Type: Review

References (65)

1. Belardelli F., Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23:2002;201-208.
2. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:2002;549-555.
3. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 12:2000;121-127.
4. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 420:2002;860-867.
5. Signore A., et al. Targeting cytokine-chemokine receptors: a challenge for molecular nuclear medicine. Eur. J. Nucl. Med. 30:2003;149-156.
6. Herberman R.B. Cancer immunotherapy with natural killer cells. Semin. Oncol. 29:2002;27-30.
7. Signore A., et al. Biological imaging for the diagnosis of inflammatory conditions. Biodrugs. 16:2002;241-259.
8. Kozak R.W., et al. Bismuth-212-labeled anti-Tac monoclonal antibody: α-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. U. S. A. 83:1986;474-478.
9. Yoo T.M., et al. Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment. J. Nucl. Med. 38:1997;294-300.
10. Carrasquillo J.A., et al. Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv. Cancer Res. 58:1998;2612-2617.
11. Van der Laken C.J., et al. Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. Eur. J. Nucl. Med. 22:1995;1249-1255.
12. Van der Laken C.J., et al. Preferential localization of systemically administered radiolabeled interleukin-1α in experimental inflammation in mice by binding to the type II receptor. J. Clin. Invest. 100:1997;2970-2976.
13. Van der Laken C.J., et al. Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: a comparative study. Eur. J. Nucl. Med. 25:1998;347-352.
14. Granowitz E.V., et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 4:1992;353-360.
15. Barrera P., et al. Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology. 39:2000;870-874.
16. Metcalf D., Nicola N.A. Tissue localization and fate in mice of injected multipotential colony-stimulating factor. Proc. Natl. Acad. Sci. U. S. A. 85:1988;3160-3164.
17. Van der Laken C.J., et al. Targeting inflammation with radiolabeled interleukin-1 and other cytokines in various mouse models. Nucl. Med. Commun. 18:1997;478.
18. 99mTc-labeled Interleukin-8. J. Nucl. Med. 42:2001;117-123.
19. Lee J., et al. Characterization of two high affinity human interleukin-8 receptors. J. Biol. Chem. 267:1992;16283-16287.
20. Gratz S., et al. Rapid imaging of experimental colitis with (99mTc)-interleukin-8 in rabbits. J. Nucl. Med. 42:2001;917-923.
21. Gratz S., et al. (99m)Tc-interleukin-8 for imaging acute osteomyelitis. J. Nucl. Med. 42:2001;1257-1264.
22. Laterveer L., et al. Rapid mobilization of hematopeitic progenitor cells in rhesus monkeys by a single intravenous injection of interleukin-8. Blood. 87:1996;781-788.
23. Gross M.D., et al. Imaging of human infection with (131)I-labeled recombinant human interleukin-8. J. Nucl. Med. 42:2001;1656-1659.
24. Welling M., et al. Detection of experimental infections with 99mTc-labeled monoclonal antibodies against TNF-α and interleukin-8. Nucl. Med. Biol. 24:1997;649-655.
25. Signore A., et al. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-interleukin-2: an early sign of type 1 diabetes. Lancet. 2:1987;537-540.
26. Chianelli M., et al. Radiopharmaceutical for the study of inflammatory processes: a review. Nucl. Med. Commun. 18:1997;437-455.
27. Signore A., et al. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J. Nucl. Med. 41:2000;242-249.
28. Annovazzi A., et al. 99mTc-Interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur. J. Nucl. Med. Mol. Imaging. 30:2003;374-382.
29. Signore A., et al. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet. Eur. J. Nucl. Med. 27:2000;18-24.
30. 123I-interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl. Med. Commun. 24:2003;305-316.
31. 123I-labelled interleukin-2. Eur. J. Endocrinol. 131:1994;431-437.
32. Signore A., et al. In vivo imaging of insulitis in autoimmune diabetes. J. Endocrinol. Invest. 22:1999;151-158.
33. Robb R.J., et al. Retention of biological activity following radioiodination of human interleukin-2: comparison with biosyntetically labelled growth factor in receptor binding assay. J. Immunol. Methods. 81:1985;15-30.
34. Gennuso R., et al. Systemic biodistribution of radioiodinated interleukin-2 in the rat. J. Biol. Response Mod. 8:1989;375-384.
35. 35S-labelled recombinant interleukin-2 in mice. Cellular and Molecular Biology of Lymphokines. 1985;Academic Press Inc.
36. Signore A., et al. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123-iodine-labelled interleukin-2: an early sign of Type 1 diabetes. Lancet. 2:1987;536-540.
37. Abbs I.C., et al. Analysis of activated T cell infiltrates in rat renal allografts by γ camera imaging after injection of 123-iodine-interleukin-2. Transpl. Immunol. 1:1993;45-51.
38. Chianelli M., et al. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl. Med. Biol. 24:1997;579-586.
39. 99mTc-Interleukin-2 scintigraphy in carotid plaques. Eur. J. Nucl. Med. 29:2002;70.
40. Manetti R., et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1993;1199-1204.
41. Barone R., et al. Radiolabelled interleukin-12 p40. A new radiopharmaceutical for imaging chronic TH1-mediated inflammation. Q. J. Nucl. Med. 42:1998;77.
42. Rollins B.J. Monocyte chemoattractant protein-1: a potential regulator of monocyte recruitment in inflammatory disease. Mol. Med. Today. 2:1996;198-204.
43. Ohtsuki K., et al. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation. 104:2001;203-208.
44. Blankenberg F.G., et al. Imaging macrophages and the apoptosis of granulocytes in a rodent model of subacute and chronic abscesses with radiolabeled monocyte chemotactic peptide-1and annexin V. Eur. J. Nucl. Med. 28:2001;1384-1393.
45. Rot A. In situ binding assay for studying chemokine interactions with endothelial cells. J. Immunol. Methods. 273:2003;63-71.
46. 99mTc-IL2 scintigraphy in patients with cutaneous melanoma: detection of lymphocytic infiltration. Eur. J. Nucl. Med. 25:1998;896.
47. McGovern V.J., et al. The classification of malignant melanoma and its histologic reporting. Cancer. 32:1973;1446-1457.
48. 125I-TGF-β-1 to fenestrated endothelium in bone and anastomosing capillary networks in enamel organ suggest a role for TGF-β-1 in angiogenesis. Calcif. Tissue Int. 68:2001;304-315.
49. Li S.R., et al. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int. J. Cancer. 91:2001;789-796.
50. 123I-labelled epidermal growth factor. Lancet. 337:1991;395-396.
51. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J. Nucl. Med. 41:2000;429-438.
52. Chen P., et al. Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and γ-radiation on EGFR-positive breast cancer cells. Nucl. Med. Biol. 29:2002;693-699.
53. Virgolini I., et al. Inhalation scintigraphy with iodine-123-labeled interferon γ-1b: pulmonary deposition and dose escalation study in healthy volunteers. J. Nucl. Med. 38:1997;1475-1481.
54. Rollins B.J. Chemokines. Blood. 90:1997;909-928.
55. Muller A., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:2001;50-56.
56. Robledo M.M., et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J. Biol. Chem. 48:2001;45098-45105.
57. Li A., et al. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin. Cancer Res. 7:2001;3298-3304.
58. Mashino K., et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62:2002;2937-2941.
59. Gunn M.D., et al. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naïve T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 95:1998;258-263.
60. Banisadr G., et al. Characterization and visualization of (125I) stromal cell-derived factor-1 α binding CXCR4 receptors in rat brain and human neuroblastoma cells. J. Neuroimmunol. 110:2000;151-160.
61. 99mTc MIBI scintimammography with a high resolution single tube γ camera: preliminary study. Anticancer Res. 17:1997;1627-1630.
62. 99mTc-Sestamibi scintimammography by SPEM camera in the management of breast cancer in the elderly. Breast Cancer Res. Treat. 48:1998;159-163.
63. Scopinaro F., et al. High-resolution scintimammography improves the accuracy of technetium-99m methoxyisobutylisonitrile scintimammography: use of a new dedicated γ camera. Eur. J. Nucl. Med. 26:1999;1279-1288.
64. Williams M.B., et al. Performance of a PSPMT based detector for scintimammography. Phys. Med. Biol. 45:2000;781-800.
65. Brem R.F., et al. High-resolution scintimammography: a pilot study. J. Nucl. Med. 43:2002;909-915.